SynthesisMedicine2025
Identification of therapeutic targets for insomnia through genetic and plasma proteomic approaches.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insomnia is a prevalent sleep disorder, and for which effective therapeutic targets remain lacking. In this study, we conducted a GWAS meta-analysis on 3 datasets: ukb-b-3957, FinnGen R10, and ebi-a-GCST004695, using METAL. Building on this, we further investigated the causality of plasma proteins using a protein Mendelian randomization (MR) approach. The MR analysis utilized protein datasets from deCODE and UKB, incorporating co-localization. Reverse MR was employed to examine the potential presence of reverse causality. MAGMA was employed to investigate key proteins associated with insomnia, along with tissue enrichment analysis. The insomnia GWAS meta-analysis revealed that 250 genes exhibited statistically significant signals after FDR correction (P < .05). A total of 81 risk loci were identified (P < 5e-8), and the risk genes were predominantly enriched in tissues such as the cerebellum, cerebellar hemisphere, and prefrontal cortex. Our PW-MR analysis identified 36 proteins with replicated causal associations with insomnia. After excluding one protein (HEXIM1) due to evidence of reverse causality, we established a final list of 35 high-confidence candidate proteins. Further colocalization analysis supported a shared causal variant for several candidates, including DNPH1 and PTK7. This study identifies a robust list of plasma proteins with genetically-predicted causal links to insomnia risk. These findings offer a valuable resource for subsequent functional validation studies aimed at elucidating the molecular mechanisms underlying the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.